Yellox | European Medicines Agency (EMA)

January 21, 2025

[ad_1]

Overview

This is a summary of the European public assessment report (EPAR) for Yellox. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Yellox.

For practical information about using Yellox, patients should read the package leaflet or contact their doctor or pharmacist.

Yellox is a medicine used in adults to treat inflammation in the eye that can occur after an operation to remove a cataract (clouding of the lens).

Yellox contains the active substance bromfenac.

Yellox is available as an eye drop solution and the recommended dose is one drop into the affected eye(s) twice a day. Treatment begins the day after the cataract operation and continues for two weeks.

If more than one eye medicine is being used, they should be given at least five minutes apart.

The medicine can only be obtained with a prescription. For more information see the package leaflet.

The active substance in Yellox, bromfenac, is a non-steroidal anti-inflammatory drug (NSAID). It works by blocking an enzyme called cyclo-oxygenase, which produces prostaglandins, substances that are involved in the inflammation process. By reducing the production of prostaglandins in the eye, Yellox can reduce the inflammation caused by eye surgery.

Yellox was found to be more effective than placebo (a dummy treatment) at relieving inflammation in the eye following cataract surgery in two main studies involving a total of 527 patients undergoing cataract surgery. In both studies, the main measure of effectiveness was the number of patients with no sign of inflammation after two weeks. In one study, 66% of patients treated with Yellox (104 out of 158) had no signs of inflammation after two weeks compared with 48% of patients receiving placebo (35 out of 73). In the second study, the figures were: 63% (124 out of 198) for patients treated with Yellox and 40% (39 out of 98) for those treated with placebo.

The most common or most important side effects seen with Yellox are abnormal sensation in eye (0.5%), mild or moderate erosion of the cornea (the transparent layer in front of the eye) (0.4%), eye pruritus (itching) (0.4%), eye pain (0.3%) and eye redness (0.3%). For the full list of all side effects reported with Yellox, see the package leaflet.

Yellox must not be used in people who are hypersensitive (allergic) to bromfenac, to any of the other ingredients or to other NSAIDs. It must not be used in patients who get asthma attacks, urticaria (itchy rash) or acute rhinitis (stuffy and runny nose) from taking acetylsalicylic acid (aspirin) or other NSAIDs.

The European Medicines Agency decided that Yellox’s benefits are greater than its risks and recommended that it be given marketing authorisation.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Yellox have been included in the summary of product characteristics and the package leaflet.

The European Commission granted a marketing authorisation valid throughout the European Union for Yellox on 18 May 2011.

For more information about treatment with Yellox, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

English (EN)
(74.45 KB – PDF)

First published: 14/06/2011Last updated: 17/11/2017

View

Product information

English (EN)
(317.2 KB – PDF)

First published: 14/06/2011Last updated: 21/01/2025

View

Latest procedure affecting product information:
II/0036/G

19/12/2024

This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

Product information documents contain:

summary of product characteristics (annex I);
manufacturing authorisation holder responsible for batch release (annex IIA);
conditions of the marketing authorisation (annex IIB);
labelling (annex IIIA);
package leaflet (annex IIIB).

English (EN)
(13.57 KB – PDF)

First published: 14/06/2011Last updated: 14/06/2011

View

Product details

Name of medicine

Yellox

Active substance

bromfenac sodium sesquihydrate

International non-proprietary name (INN) or common name

bromfenac

Therapeutic area (MeSH)

Pain, Postoperative
Ophthalmologic Surgical Procedures

Anatomical therapeutic chemical (ATC) code

S01BC11

Pharmacotherapeutic group

Ophthalmologicals

Therapeutic indication

Treatment of postoperative ocular inflammation following cataract extraction in adults.

[ad_2]

Source link

Yellox | European Medicines Agency (EMA)

Overview

Product information

Product details

Pharmacotherapeutic group

Therapeutic indication

NO COMMENTS

LEAVE A REPLY Cancel reply

Overview

What is Yellox and what is it used for?

How is Yellox used?

How does Yellox work?

What benefits of Yellox have been shown during the studies?

What are the risks associated with Yellox?

Why is Yellox approved?

What measures are being taken to ensure the safe and effective use of Yellox?

Other information about Yellox

Product information

Product details

Pharmacotherapeutic group

Therapeutic indication

RELATED ARTICLES

Ebvallo | European Medicines Agency (EMA)

Cimzia | European Medicines Agency (EMA)

Erbitux | European Medicines Agency (EMA)

NO COMMENTS

LEAVE A REPLY Cancel reply